Comprehensive landscape of the functions and prognostic value of RNA binding proteins in uterine corpus endometrial carcinoma

Abstract

Background: The dysregulation of RNA binding proteins (RBPs) is involved in tumorigenesis and progression. However, information on the overall function of RNA binding proteins in Uterine Corpus Endometrial Carcinoma (UCEC) remains to be studied. This study aimed to explore Uterine Corpus Endometrial Carcinoma-associated molecular mechanisms and develop an RNA-binding protein-associated prognostic model.Methods: Differently expressed RNA binding proteins were identified between Uterine Corpus Endometrial Carcinoma tumor tissues and normal tissues by R packages (DESeq2, edgeR) from The Cancer Genome Atlas (TCGA) database. Hub RBPs were subsequently identified by univariate and multivariate Cox regression analyses. The cBioPortal platform, R packages (ggplot2), Human Protein Atlas (HPA), and TIMER online database were used to explore the molecular mechanisms of Uterine Corpus Endometrial Carcinoma. Kaplan-Meier (K-M), Area Under Curve (AUC), and the consistency index (c-index) were used to test the performance of our model.Results: We identified 128 differently expressed RNA binding proteins between Uterine Corpus Endometrial Carcinoma tumor tissues and normal tissues. Seven RNA binding proteins genes (NOP10, RBPMS, ATXN1, SBDS, POP5, CD3EAP, ZC3H12C) were screened as prognostic hub genes and used to construct a prognostic model. Such a model may be able to predict patient prognosis and acquire the best possible treatment. Further analysis indicated that, based on our model, the patients in the high-risk subgroup had poor overall survival (OS) compared to those in the low-risk subgroup. We also established a nomogram based on seven RNA binding proteins. This nomogram could inform individualized diagnostic and therapeutic strategies for Uterine Corpus Endometrial Carcinoma.Conclusion: Our work focused on systematically analyzing a large cohort of Uterine Corpus Endometrial Carcinoma patients in the The Cancer Genome Atlas database. We subsequently constructed a robust prognostic model based on seven RNA binding proteins that may soon inform individualized diagnosis and treatment.

Prognostic evaluation of the novel blueprint of DNA methylation sites by integrating bulk RNA‐sequencing and methylation modification data in endometrial cancer

“…Nevertheless, approximately 20% of patients remain asymptomatic and are diagnosed at advanced stages, characterized by local spread or distant metastases, resulting in a significantly lower 5-year survival rate of 68% and 17%, respectively. 6 Comprehensive long-term follow-up studies are necessary for the development of personalized management approaches for achievement of optimal treatment and improved cancer patient outcomes. 7,8 DNA methylation is a well-studied epigenetic modification that plays a crucial role in cancer progression.…”

“…This early diagnosis is associated with a favorable prognosis, as evidenced by a 5‐year survival rate exceeding 95%. Nevertheless, approximately 20% of patients remain asymptomatic and are diagnosed at advanced stages, characterized by local spread or distant metastases, resulting in a significantly lower 5‐year survival rate of 68% and 17%, respectively 6 . Comprehensive long‐term follow‐up studies are necessary for the development of personalized management approaches for achievement of optimal treatment and improved cancer patient outcomes 7,8 …”